Jamjoom Pharmaceuticals Factory Company
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Jamjoom Pharmaceuticals Factory Company's yearly results (2022–2025), compared with Healthcare companies in Saudi Arabia. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 125.4 times by its yearly operating cash. Higher than 96% of Healthcare companies in Saudi Arabia.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 4% of its market value (net cash). Higher than 96% of Healthcare companies in Saudi Arabia.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 5.5 times. Higher than 88% of Healthcare companies in Saudi Arabia.
Where SAR 100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
SAR 87Over the last 3 years, every SAR 100 of reported profit came with SAR 87 of operating cash.
Lower than 79% of Healthcare companies in Saudi Arabia.
Self-Funding Ratio
5.5×Over the last 3 years its own operating cash covered its investment spending (capex) 5.5 times.
Higher than 88% of Healthcare companies in Saudi Arabia.
Cash Locked Ratio
SAR 50For every SAR 100 of sales, SAR 50 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against SAR 46 tied up three years earlier.
More money tied up than 71% of Healthcare companies in Saudi Arabia.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 75% of Healthcare companies in Saudi Arabia.
Growth Efficiency Ratio
SAR 50Sales grew 64% in 3 years; of every extra SAR 100 of sales, SAR 50 became extra profit.
Higher than 88% of Healthcare companies in Saudi Arabia.
Asset Productivity Ratio
+64% / +45%In 3 years sales changed by +64% while total assets changed by +45%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
125.4×Debt due within a year is covered 125.4 times by its yearly operating cash.
Higher than 96% of Healthcare companies in Saudi Arabia.
Cash Cushion Ratio
+4%Cash, after subtracting all debt, equals 4% of its market value (net cash).
Higher than 96% of Healthcare companies in Saudi Arabia.
Tangible Assets Ratio
99%Of every SAR 100 the company owns, SAR 99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 68% of Healthcare companies in Saudi Arabia.
Tangible Net Worth Ratio
99%Of every SAR 100 of net worth, SAR 99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 86% of Healthcare companies in Saudi Arabia.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Jamjoom Pharmaceuticals Factory Company owes SAR 0.20 for every SAR 1 it owns. Net profit rose 30% in the year to Dec 2025, and grew 39% a year on average over 3 years.
Compared with Healthcare companies in Saudi Arabia · latest annual results Dec 2025.
P/E ratio
17.6Investors pay SAR 17.6 for every SAR 1 of Jamjoom Pharmaceuticals Factory Company's yearly profit, higher than 79% of Healthcare companies in Saudi Arabia.
P/B ratio
4.51The share price is 4.51 times Jamjoom Pharmaceuticals Factory Company's book value per share, higher than 88% of Healthcare companies in Saudi Arabia.
Market cap
SAR 8.5 BThe total market value of all of Jamjoom Pharmaceuticals Factory Company's shares at today's price (share price × number of shares), larger than 71% of Healthcare companies in Saudi Arabia. PosiCap size class: Meso Cap.
Net worth (book value)
SAR 1.9 BWhat Jamjoom Pharmaceuticals Factory Company would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
SAR 26.83Net worth divided by the number of shares. The share price of SAR 121.00 is 4.5 times this, which is the P/B above.
Return on equity (ROE)
27.0%Jamjoom Pharmaceuticals Factory Company earned 27.0% on its shareholders' money over the last year, higher than 77% of Healthcare companies in Saudi Arabia.
Owes vs Owns
0.20×Jamjoom Pharmaceuticals Factory Company owes SAR 0.20 for every SAR 1 it owns (low), lower than 96% of Healthcare companies in Saudi Arabia.
Dividend yield
3.53%Jamjoom Pharmaceuticals Factory Company pays 3.53% of its share price as dividends a year, higher than 54% of dividend-paying Healthcare companies in Saudi Arabia.
Revenue growth
+14%Revenue rose 14% in the year to Dec 2025, and grew 18% a year on average over 3 years.
Profit growth
+30%Net profit rose 30% in the year to Dec 2025, and grew 39% a year on average over 3 years.
Profit margin
30.9%Jamjoom Pharmaceuticals Factory Company keeps SAR 31 of every SAR 100 of revenue as net profit.
Cash quality
0.9×Cash from Jamjoom Pharmaceuticals Factory Company's business was 0.9× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Interest cover
2480.1×Jamjoom Pharmaceuticals Factory Company's operating profit covered its interest costs 2480.1 times in the year to Dec 2025.
Cash vs debt
Net cashJamjoom Pharmaceuticals Factory Company held SAR 342 M more cash than debt (net cash) at Dec 2025.
Questions
What is Jamjoom Pharmaceuticals Factory Company's P/E ratio?
Investors pay SAR 17.6 for every SAR 1 of Jamjoom Pharmaceuticals Factory Company's yearly profit, higher than 79% of Healthcare companies in Saudi Arabia.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Jamjoom Pharmaceuticals Factory Company: SAR 8.5 B ÷ SAR 1.9 B (30 Jun 2026) = 4.5.
What is Jamjoom Pharmaceuticals Factory Company's return on equity?
Jamjoom Pharmaceuticals Factory Company earned 27.0% on its shareholders' money over the last year, higher than 77% of Healthcare companies in Saudi Arabia.
How much does Jamjoom Pharmaceuticals Factory Company owe compared with what it owns?
Jamjoom Pharmaceuticals Factory Company owes SAR 0.20 for every SAR 1 it owns (low), lower than 96% of Healthcare companies in Saudi Arabia.
Does Jamjoom Pharmaceuticals Factory Company pay a dividend?
Yes. Jamjoom Pharmaceuticals Factory Company pays 3.53% of its share price as dividends a year, higher than 54% of dividend-paying Healthcare companies in Saudi Arabia.
Is Jamjoom Pharmaceuticals Factory Company's revenue growing?
Revenue rose 14% in the year to Dec 2025, and grew 18% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.